Durvalumab and
Durvalumab with tremelimumab with Chemotherapy
Serious
chemotherapy chemotherapy alone
adverse reaction
(out of 265 (out of 266 (out of 266
participants) participants) participants)
Type 1 diabetes 0.8% (2) 0.4% (1) 0.0% (0)
General worsening health 0.8% (2) 0.4% (1) 0.0% (0)
Low levels of sodium in the blood 0.0% (0) 0.4% (1) 0.8% (2)
Nausea 0.0% (0) 0.4% (1) 0.8% (2)
Vomiting 0.0% (0) 0.4% (1) 0.8% (2)
Lung infection 0.0% (0) 0.4% (1) 0.4% (1)
Kidney injury 0.8% (2) 0.0% (0) 0.8% (2)
Blood infection 0.4% (1) 0.0% (0) 0.4% (1)
General weakness 0.4% (1) 0.0% (0) 0.4% (1)
Low levels of potassium in the blood 0.0% (0) 0.0% (0) 0.8% (2)
There were 2.5% of participants who died because of serious adverse reactions.
This was 20 out of 797 participants.
> 2.3% of participants who got durvalumab with chemotherapy died because of
serious adverse reactions. This was 6 out of 265 participants.
> 4.5% of participants who got durvalumab and tremelimumab with
chemotherapy died because of serious adverse reactions. This was 12 out of
266 participants.
> 0.8% of participants who got chemotherapy alone died because of serious
adverse reactions. This was 2 out of 266 participants.
What adverse reactions happened during this study?
The most common adverse reaction was having very low levels of a type of white
blood cell called a neutrophil.
14 | Clinical Study Results